Clare Kahn, Ph.D. has served as a member of Solid’s Board of Directors since March 2021 and has served as a consultant to Solid since June 2022.
Dr. Kahn served as R&D Strategy Officer at X-VAX Technology Inc., a biotechnology company developing vaccines against pathogens acquired by mucosal infection such as herpes, from September 2019 until November 2023. She served as Chief Regulatory and Preclinical Development Officer at X-VAX from September 2018 to September 2019.
Dr. Kahn has also been the president of Clare Kahn Pharma Consulting LLC, through which she provides consulting services on regulatory strategy since July 2016. Dr. Kahn was previously Vice President, Worldwide Regulatory Strategy, Global Innovative Pharma at Pfizer from January 2014 to June 2016 and Vice President, Worldwide Regulatory Strategy, Specialty Care Business at Pfizer from June 2010 to December 2013. Prior to Pfizer, she was Vice President of Regulatory Affairs for a variety of therapeutic areas including cardiovascular, metabolic, urology, oncology and vaccines at GlaxoSmithKline from 1999 to 2010.
Dr. Kahn has a Ph.D. in Biochemical Pharmacology from The Royal Postgraduate Medical School, London and served as Assistant Professor of Pharmacology and of Pathology and Laboratory Medicine at The University of Pennsylvania from 1981 to 1985.
What is Clare Kahn's net worth?
The estimated net worth of Clare Kahn is at least $17.52 thousand as of March 11th, 2025. Dr. Kahn owns 2,960 shares of Solid Biosciences stock worth more than $17,523 as of December 4th. This net worth estimate does not reflect any other investments that Dr. Kahn may own. Learn More about Clare Kahn's net worth.
How do I contact Clare Kahn?
Has Clare Kahn been buying or selling shares of Solid Biosciences?
Clare Kahn has not been actively trading shares of Solid Biosciences during the last quarter. Most recently, on Tuesday, March 11th, Clare Kahn bought 1,860 shares of Solid Biosciences stock. The stock was acquired at an average cost of $5.34 per share, with a total value of $9,932.40. Following the completion of the transaction, the director now directly owns 2,960 shares of the company's stock, valued at $15,806.40. Learn More on Clare Kahn's trading history.
Who are Solid Biosciences' active insiders?
Are insiders buying or selling shares of Solid Biosciences?
During the last twelve months, Solid Biosciences insiders bought shares 1 times. They purchased a total of 1,860 shares worth more than $9,932.40. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 31,092 shares worth more than $155,239.01. The most recent insider tranaction occured on December, 3rd when COO David T Howton sold 4,932 shares worth more than $25,202.52. Insiders at Solid Biosciences own 1.9% of the company.
Learn More about insider trades at Solid Biosciences. Information on this page was last updated on 12/3/2025.
